Page 56 - GALENIKA MEDICAL JOURNAL

C, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the 24. Fox KA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Raedt H,
diagnosis and management of chronic coronary syndromes. Eur Heart et al. Underestimated and under-recognized: the late consequences of
J. 2020 Jan 14;41(3):407-7. acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J. 2010
Nov;31(22):2755-64.
6. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al.
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management 25. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al.
of Patients With Chronic Coronary Disease: A Report of the American REACH Registry Investigators. Comparative determinants of 4-year
Heart Association/American College of Cardiology Joint Committee on cardiovascular event rates in stable outpatients at risk of or with
Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-e119. atherothrombosis. JAMA. 2010 Sep 22;304(12):1350-7.
7. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour 26. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon
LM, et al. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases L, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines
Writing Group. Global Burden of Cardiovascular Diseases and Risk for the management of dyslipidaemias: lipid modification to reduce
Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.
2020 Dec 22;76(25):2982-3021.
27. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. DA
8. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck VINCI study. EU-Wide Cross-Sectional Observational Study of Lipid-
M, et al. ESC Scientific Document Group. 2021 ESC Guidelines on Modifying Therapy Use in Secondary and Primary Care: the DA VINCI
cardiovascular disease prevention in clinical practice: Developed by the study. Eur J Prev Cardiol. 2021 Sep 20;28(11):1279-89.
Task Force for cardiovascular disease prevention in clinical practice with
representatives of the European Society of Cardiology and 12 medical 28. Burazor I, Cosic Z, Babic R, Otasevic P, Tasic N, Kostic S: Optimization
societies With the special contribution of the European Association of lipids for prevention in patients with documented atherosclerotic
of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022 cardiovascular diseases. Our experiences. Atherosclerosis 2022, 353:
May;75(5):429. 254
9. Keys A, Menotti A, Aravanis C, Blackburn H, Djordevic BS, Buzina R, et 29. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al.
al. The seven countries study: 2,289 deaths in 15 years. Prev Med. 1984 REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent
Mar;13(2):141-54. Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22.
10. Menotti A, Puddu P. Mediterranean adequacy index: Features and 30. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L,
applications, in: Preedy V, Watson R, (eds)The Mediterranean Diet et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic
(Second Edition), Academic Press,2020: 111-7 stenosis: a European Atherosclerosis Society consensus statement. Eur
Heart J. 2022 Oct 14;43(39):3925-46.
11. Salzwedel A, Jensen K, Rauch B, Doherty P, Metzendorf MI, Hackbusch
M, et al. Effectiveness of comprehensive cardiac rehabilitation in 31. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes
coronary artery disease patients treated according to contemporary MJ, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the
evidence based medicine: Update of the Cardiac Rehabilitation management of cardiovascular disease in patients with diabetes. Eur
Outcome Study (CROS-II). Eur J Prev Cardiol. 2020 Nov;27(16):1756-74. Heart J. 2023 Oct 14;44(39):4043-140.
12. Kabboul NN, Tomlinson G, Francis TA, Grace SL, Chaves G, Rac V, et 32. Janković SM, Stojković S, Petrović M, Kostić T, Zdravković M, Radovanović
al. Comparative Effectiveness of the Core Components of Cardiac S, et al. Results of the trycort: Cohort study of add-on antihypertensives
Rehabilitation on Mortality and Morbidity: A Systematic Review and for treatment of resistant hypertension. Medicine (Baltimore). 2023 Jun
Network Meta-Analysis. J Clin Med. 2018 Dec 4;7(12):514. 2;102(22):e33941.
13. Abreu A, Frederix I, Dendale P, Janssen A, Doherty P, Piepoli MF, et al. 33. Koenig W. High-sensitivity C-reactive protein and atherosclerotic
Secondary Prevention and Rehabilitation Section of EAPC Reviewers: disease: from improved risk prediction to risk-guided therapy. Int J
Standardization and quality improvement of secondary prevention Cardiol. 2013 Oct 15;168(6):5126-34.
through cardiovascular rehabilitation programmes in Europe: The 34. Kotseva K; EUROASPIRE Investigators. The EUROASPIRE surveys:
avenue towards EAPC accreditation programme: A position statement lessons learned in cardiovascular disease prevention. Cardiovasc Diagn
of the Secondary Prevention and Rehabilitation Section of the European Ther. 2017 Dec;7(6):633-9.
Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol. 2021
May 14;28(5):496-509. 35. De Bacquer D, Ueda P, Reiner Ž, De Sutter J, De Smedt D, Lovic D, et al.
EUROASPIRE IV and V National Coordinators. Prediction of recurrent
14. Andersson C, Johnson AD, Benjamin EJ, Levy D, Vasan RS. 70-year legacy event in patients with coronary heart disease: the EUROASPIRE Risk
of the Framingham Heart Study. Nat Rev Cardiol. 2019 Nov;16(11):687- Model. Eur J Prev Cardiol. 2022 Mar 11;29(2):328-39.
98.
36. Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, et
15. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches al. Estimation of recurrent atherosclerotic cardiovascular event risk in
to heart disease: the Framingham Study. Am J Public Health Nations patients with established cardiovascular disease: the updated SMART2
Health. 1951 Mar;41(3):279-81. algorithm. Eur Heart J. 2022 May 7;43(18):1715-27.
16. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of 37. Klooster CCV', Bhatt DL, Steg PG, Massaro JM, Dorresteijn JAN,
risk in the development of coronary heart disease--six year follow-up Westerink J, et al. UCC-SMART study group. Predicting 10-year risk of
experience. The Framingham Study. Ann Intern Med. 1961 Jul;55:33-50. recurrent cardiovascular events andcardiovascular interventions in
17. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: patients with established cardiovascular disease: results from UCC-
the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A- SMART and REACH. Int J Cardiol. 2021 Feb 15;325:140-8.
13A. 38. Castelijns MC, Helmink MAG, Hageman SHJ, Asselbergs FW, de Borst GJ,
18. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Bots ML, et al. Cohort profile: the Utrecht Cardiovascular Cohort-Second
Independent risk factors for atrial fibrillation in a population-based Manifestations of Arterial Disease (UCC-SMART) Study-an ongoing
cohort. The Framingham Heart Study. JAMA. 1994 Mar 16;271(11):840-4. prospective cohort study of patients at high cardiovascular risk in the
Netherlands. BMJ Open. 2023 Feb 20;13(2):e066952.
19. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial
infarction: the Framingham study. Am J Cardiol. 1979 Jul;44(1):53-9. 39. Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D'Agostino RB
Sr, Massaro JM, et al. Estimated Life Expectancy Without Recurrent
20. Brand FN, Larson M, Friedman LM, Kannel WB, Castelli WP. Cardiovascular Events in Patients With Vascular Disease: The SMART-
Epidemiologic assessment of angina before and after myocardial REACH Model. J Am Heart Assoc. 2018 Aug 21;7(16):e009217.
infarction: The Framingham study. Am Heart J. 1996 Jul;132(1 Pt 1):174-
8.
21. De Vreede JJ, Gorgels AP, Verstraaten GM, Vermeer F, Dassen WR, Konflikt interesa: Nema
Wellens HJ. Did prognosis after acute myocardial infarction change
during the past 30 years? A meta-analysis. J Am Coll Cardiol. 1991 Primljeno: 05. 02. 2024.
Sep;18(3):698-706. Prihvaćeno: 19. 02. 2024.
22. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a prognostic Onlajn: 31. 03. 2024.
factor after myocardial infarction: the Framingham Study. Ann Intern
Med. 1991 Nov 1;115(9):687-93.
23. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon
M. Cardiovascular risk in post-myocardial infarction patients:
nationwide real world data demonstrate the importance of a long-term
perspective. Eur Heart J. 2015 May 14;36(19):1163-70.

54 DOI: 10.5937/Galmed2409049B